Crispr-cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the alzheimer`s disease psen1 m146l mutation

HIGHLIGHTS

• who: Evangelos Konstantinidis from the Laboratory Uppsala University Toronto, Toronto, ON, Canada have published the Article: CRISPR-Cas9 treatment partially restores amyloid-u03b2 42/40 in human fibroblasts with the Alzheimer`s disease PSEN1 M146L mutation, in the Journal: (JOURNAL) of 28/06/2022
• what: The authors aimed to evaluate whether specific disruption of the PSEN1M146L allele in PSEN1M146L/WT fibroblasts leads to a normalized Ab42/40 ratio and whether this change has any effect on the altered PS1 conformation associated with the mutation. The authors aimed to specifically target presenilin 1, the catalytic subunit . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.